Why Spring Bank Pharmaceuticals, Inc. (SBPH) Jumped 5.87% in Thursday’s Stock Market

Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) is trending higher in the market today as the company shares are trading 5.87% or 0.3 points up from last closing price of $5.11, reaching $5.41 at last check. Any clue why there is so much of action in the SBPH stock? The share price is gaining for the third day in a row and has risen in 4 of the last 5 days and is down -43.22% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -43,858 shares, and in total 51842 shares valued at $280465 were seen changing hands compared with 95700 shares valued at $489027 recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in SBPH stock for the next couple of days.

Spring Bank Pharmaceuticals, Inc. (SBPH) shares have notched a 3-month decline of about -43.22%, but has still tumbled -50.82% year to date. By comparison, the stock sank -56.44% over the past 12 months, while it jumped 17.47% over the 1 month. The company’s market cap is around $89.27M, with its short interest ratio standing at 2.8%.

In the current trading session for SBPH, the stock witnessed two major price actions, it rose to a high of $5.62 and was down as much as $5.12 at one point. The high recorded is very low when compared to their 52-week high which is $3.58. The 52-week high is now at -64.87 distance from current price. Their recent low of $15 represents a 47.21% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for SBPH is $21.92, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The company recorded an interesting insider purchase transaction by the Director on Jun 28, 2019. A Securities and Exchanges Commission filings show that Scott Andrew Smith bought a total of 12,000 SBPH shares that day for a sum of around $49,080. Spring Bank Pharmaceuticals, Inc. (SBPH) insiders have acquired 58,023 shares in the stock within the past three months. In total, individual insiders traded 58,023 shares in the business, which makes up 79.99% of 72,538 shares that were traded over a year. In the past 12 months, insiders have purchased 72,538 shares while the seller parted with shares.

SBPH‘s last price was down -42.73% as compared to the average trading price of 50 days recorded at $9.45 while enlarging the period to 200 trading days, the average closing price was $5.47. At present, there are 17.47 million in the total number of common shares owned by the public and among those 13.24 million shares have been available to trade. The percentage of shares being held by the company management was 1% while institutions stake was 43.4%. The company has generated negative returns on equity over the last 12 months (-46.7%). It managed to keep its gross profit margin at 0% over the past 12 months.

When assessing the full upside of the SBPH stock, there is another set of technicals that should be looked into and considered. Its 19.28% gain from moving average of $4.54 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Spring Bank Pharmaceuticals, Inc. — 5 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $23 on shares of Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), which corresponds to 334.78% upside potential than its current market price of $5.41 and implies potential despite the recent advance in the price. However, their current target price has fallen from $26.75 a month ago and is down handily from the consensus target of $26.75 a quarter ago.

In the last five years, the EPS of the company has been roughly -10.1%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.

Let’s briefly check the hedge fund interest towards SBPH stock. Morse Asset Management Inc trimmed position in the company after it dumped -11.6% or 168,750 shares of its common stock. The hedge fund now owns 149,175 shares worth $807,037, SEC documents show. BNP Paribas Arbitrage SA shored up assets in the stock as 197 shares have been purchased, increasing its stake by 1395.4% to 2,946 shares which are currently valued at $15,938. In addition, Deutsche Bank AG recently reported that it now owns 18,136 shares making a total of $98,116 based on the recent price. This refelects a change of -37% in their ownership.